Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Melinda M. Przetak"'
Publikováno v:
FEBS letters. 364(3)
A serine protease gene was cloned from cDNA prepared from tissue isolated from human ascites. The gene codes for a protein of 264 amino acids, identified as human granzyme 3 by the N-terminal amino acid sequence. Granzyme 3 has the expected features
Autor:
Kirk J. Hayenga, Randy M. Berka, Daniel Cullen, Michael W. Rey, Nigel Dunn-Coleman, Michael H. Lamsa, Ronald A. Hitzeman, Lori J. Wilson, Frank T. Bayliss, Katherine H. Kodama, Peggy Bloebaum, Melinda M. Przetak, Michael Ward
Publikováno v:
Applications of Enzyme Biotechnology ISBN: 9781475792379
Among the diversity of cellular systems that have been developed for the expression of heterologous gene products, certain species of filamentous fungi possess features which make them exceptionally attractive for this purpose. These include (a) the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5f38c87ff00b314e2dc1eba7c9d6ae5
https://doi.org/10.1007/978-1-4757-9235-5_21
https://doi.org/10.1007/978-1-4757-9235-5_21
Autor:
Deshmukh A; Research Unit - Neuroscience and Immunology, EMD Serono, Billerica, Massachusetts (A.D., A.P., N.G., E.T., M.P., M.D.C., A.T. B., B.V.) and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (E.F.M.)., Pereira A; Research Unit - Neuroscience and Immunology, EMD Serono, Billerica, Massachusetts (A.D., A.P., N.G., E.T., M.P., M.D.C., A.T. B., B.V.) and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (E.F.M.)., Geraci N; Research Unit - Neuroscience and Immunology, EMD Serono, Billerica, Massachusetts (A.D., A.P., N.G., E.T., M.P., M.D.C., A.T. B., B.V.) and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (E.F.M.)., Tzvetkov E; Research Unit - Neuroscience and Immunology, EMD Serono, Billerica, Massachusetts (A.D., A.P., N.G., E.T., M.P., M.D.C., A.T. B., B.V.) and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (E.F.M.)., Przetak M; Research Unit - Neuroscience and Immunology, EMD Serono, Billerica, Massachusetts (A.D., A.P., N.G., E.T., M.P., M.D.C., A.T. B., B.V.) and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (E.F.M.)., Catalina MD; Research Unit - Neuroscience and Immunology, EMD Serono, Billerica, Massachusetts (A.D., A.P., N.G., E.T., M.P., M.D.C., A.T. B., B.V.) and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (E.F.M.)., Morand EF; Research Unit - Neuroscience and Immunology, EMD Serono, Billerica, Massachusetts (A.D., A.P., N.G., E.T., M.P., M.D.C., A.T. B., B.V.) and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (E.F.M.)., Bender AT; Research Unit - Neuroscience and Immunology, EMD Serono, Billerica, Massachusetts (A.D., A.P., N.G., E.T., M.P., M.D.C., A.T. B., B.V.) and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (E.F.M.)., Vaidyanathan B; Research Unit - Neuroscience and Immunology, EMD Serono, Billerica, Massachusetts (A.D., A.P., N.G., E.T., M.P., M.D.C., A.T. B., B.V.) and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia (E.F.M.) bharat.vaidyanathan@emdserono.com.
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2024 Feb 15; Vol. 388 (3), pp. 751-764. Date of Electronic Publication: 2024 Feb 15.
Autor:
Vlach J; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Bender AT; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.) andrew.bender@emdserono.com., Przetak M; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Pereira A; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Deshpande A; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Johnson TL; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Reissig S; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Tzvetkov E; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Musil D; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Morse NT; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Haselmayer P; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Zimmerli SC; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Okitsu SL; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Walsky RL; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.)., Sherer B; EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts (J.V., A.T.B., M.P., A.P., A.D., T.J., E.T., N.T.M., S.F.Z., S.L.O., R.W., B.S.) and Merck KGaA, Darmstadt, Germany (S.R., D.M., P.H.).
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2021 Mar; Vol. 376 (3), pp. 397-409. Date of Electronic Publication: 2020 Dec 16.
Autor:
Mullarkey M; Biology Section, Eisai Research Institute of Boston, Inc., Andover, Massachusetts, USA., Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2003 Mar; Vol. 304 (3), pp. 1093-102.
Autor:
Przetak M; Department of Molecular Biology and Biochemistry, Signal Transduction Research, 4 Corporate Drive, Andover, MA 01810, USA., Chow J, Cheng H, Rose J, Hawkins LD, Ishizaka ST
Publikováno v:
Vaccine [Vaccine] 2003 Feb 14; Vol. 21 (9-10), pp. 961-70.
Autor:
Hawkins LD; Department of Medicinal Chemistry, Signal Transduction Research, Eisai Research Institute, Andover, Massachusetts 01810, USA., Ishizaka ST, McGuinness P, Zhang H, Gavin W, DeCosta B, Meng Z, Yang H, Mullarkey M, Young DW, Yang H, Rossignol DP, Nault A, Rose J, Przetak M, Chow JC, Gusovsky F
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2002 Feb; Vol. 300 (2), pp. 655-61.